Available Until 11/9/2025

What’s the Risk? Update on the Safe Use of Medicines in Patients with G6PD Deficiency

Planned in cooperation with the ASHP Section of Clinical Specialists and Scientists 

ACPE Activity Number: 0204-0000-22-166-H01-P
Release Date: Nov 9, 2022 
Expiration Date: Nov 9, 2025 
Activity Type: Knowledge-based 
CE Credits:  1.0 contact hour, (0.10 CEU)
Activity Fee: Member – Free / Non-Member – Not Available 

This activity is a recording from a live webinar and those that claim credit for the live webinar should not claim credit for this activity.

Activity Overview 

The Clinical Pharmacogenetics Implementation Consortium (CPIC) recently published a peer-reviewed clinical practice guideline titled “Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype” (Clin Pharmacol Ther 2022 In press). This updated CPIC guideline provides clear evidence-based recommendations for personalizing therapy in people with G6PD deficiency.  This session will provide attendees with the consensus recommendations found in the 2022 CPIC guideline, which reviews the evidence for 48 medications cited by one or more sources as being potentially unsafe in the setting of G6PD deficiency. The update to the guideline classifies these medications as high, medium, or low-to-no risk based on a systematic review of published evidence of gene-drug associations and regulatory warnings. Based on this review, high risk medications now include dapsone, methylene blue, pegloticase, standard-or-high-dose primaquine, rasburicase, tafenoquine, and toluidine blue.  In patients with G6PD deficiency, high-risk medications should be avoided, medium risk medications should be used with caution, and low-to-no risk medications can be used without regard to G6PD phenotype. The audience will gain knowledge about how to personalize patients’ therapy in the context of G6PD deficiency. 


The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity was planned to meet the educational needs of pharmacists who have direct patient care activities in the hospital setting, ambulatory care setting, and in the community. 

After completing this activity, the learner should be able to… 

1. Describe the hematological parameters known to interfere with G6PD activity testing. 

2. Summarize how to assign G6PD phenotype. 

3. Discuss the safe use of medications in patients who are G6PD deficient. 

  • Introduction and Announcements 

  • Presentation  

  • Questions, Answers, and Discussion 

Cyrine-Eliana Haidar, PharmD, BCPS, BCOP, FASHP
Clinical Pharmacogenetics Coordinator
St. Jude Children’s Research Hospital
Memphis, TN

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

  • No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

This activity consists of recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity. 

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.